Skip to main content

Table 4 Relationship between trough blood concentration and side effects observed in patients taking bosutinib

From: Correlation of plasma concentration and adverse effects of bosutinib: standard dose or dose-escalation regimens of bosutinib treatment for patients with chronic myeloid leukemia

 

Distribution of C0

P

Q1

Q2–3

Q4

Liver dysfunction

 ≥ grade 1

6/34

29/68

15/34

0.019

 ≥ grade 2

0/34

2/68

4/34

0.050

 ≥ grade 3–4

0/34

1/68

2/34

0.231

Diarrhea

 ≥ grade 1

5/34

8/68

6/34

0.714

 ≥ grade 2

1/34

2/68

5/34

0.041

 ≥ grade 3

1/34

0/68

4/34

0.012

  1. Q quantile, C 0 trough blood concentration. Q1 (≤ 32.5), Q2 (> 32.5), Q3 (≤ 91.0), Q4 (> 91.0). Median C0 = 54.0 (ng/mL)
Back to article page

Experimental Hematology & Oncology

ISSN: 2162-3619

Contact us